 Allogene has potential to have the first pivotal phase 2 study using its allogeneic CAR-T known as ALLO-501A for the treatment of patients with non-Hodgkins Lymphoma. Trial results are to be released from several long-term follow-up studies including ALPHA, ALPHA2 and UNIVERSAL by end of 2022. 